The Dow Jones Industrial Average surged 426 points, or 0.9%, on Thursday as Wall Street rediscovered its appetite for large-cap stocks.The S&P 500 climbed 0.7% The Dow Jones Industrial Average surged 426 points, or 0.9%, on Thursday as Wall Street rediscovered its appetite for large-cap stocks.The S&P 500 climbed 0.7%

US midday market brief: Dow gains over 400 points as investors rotate to blue chips

The Dow Jones Industrial Average surged 426 points, or 0.9%, on Thursday as Wall Street rediscovered its appetite for large-cap stocks.

The S&P 500 climbed 0.7% while the Nasdaq advanced 0.9%, signaling a broad market rebound driven by a resurgence in semiconductor stocks and unexpectedly strong bank earnings.

The rally marked a decisive pivot from earlier-week headwinds tied to geopolitical tensions and Federal Reserve concerns, underscoring how quickly investor sentiment can shift when earnings and economic data support risk appetite.​

Chip sector leads after Taiwan semi’s bullish 2026 capex plan

Taiwan Semiconductor Manufacturing Company delivered a blockbuster earnings report that reset the narrative around artificial intelligence demand.

The company posted fourth-quarter revenues of $33.1 billion, up 20.5% year-over-year, and announced a staggering 2026 capital expenditure budget of $52 billion to $56 billion, a 37% increase from 2025’s $40.9 billion spending.

The upside surprise was unmistakable.

Markets had expected capex closer to $48–$50 billion, so TSMC’s aggressive commitment signaled unwavering confidence in sustained demand for AI chip-making capacity.​

For investors, the number matters enormously. When TSMC commits to massive capex, it cascades through the supply chain.

Equipment makers like ASML, Applied Materials, and semiconductor design firms benefit from the orders required to build out fabs.

TSMC shares jumped more than 6%, while the VanEck Semiconductor ETF (SMH) climbed 3.34% in pre-market trading.

NVIDIA and AMD each gained more than 2%. The message was clear: the AI boom isn’t showing signs of weakening, and the need for advanced chip capacity will be sustained for years.​

Banks climb, and oil pullback adds momentum

Meanwhile, Wall Street’s biggest investment banks delivered a one-two punch.

Goldman Sachs reported a 12% profit increase to $4.62 billion in net income, with deal-making fees surging 25% year-over-year.

Morgan Stanley topped expectations with a 18% profit jump to $4.4 billion, powered by a 47% revenue surge in investment banking, evidence that corporate mergers and acquisitions activity remains robust.

Both stocks climbed sharply, with Goldman advancing 4% and Morgan Stanley nearly 6%, each reaching fresh 52-week highs.​

The rotation into blue chips received additional support from labor market confirmation and energy relief.

Weekly jobless claims came in at 198,000 for the week ending January 10, beating expectations of 215,000 and signaling labor market resilience without overheating.

Separately, Brent crude oil plummeted more than 4%, to around $63.69 per barrel, after President Trump signaled a pause on potential military action against Iran, easing fears of a Middle East supply disruption.

Lower oil prices reduce inflation pressure on the broader economy, a development that tends to lift cyclical and financial stocks.​

The combination of TSMC’s capex confidence, bank earnings resilience, and improving economic signals sets up favorable conditions for a sustained rally if momentum holds.

The post US midday market brief: Dow gains over 400 points as investors rotate to blue chips appeared first on Invezz

Market Opportunity
4 Logo
4 Price(4)
$0.02588
$0.02588$0.02588
-3.28%
USD
4 (4) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23